Literature DB >> 28695724

Contribution of medications and risk factors to QTc interval lengthening in the atherosclerosis risk in communities (ARIC) study.

Khalid A Alburikan1, Ahmed Aldemerdash2, Samuel T Savitz3, James E Tisdale4, Eric A Whitsel3,5, Elsayed Z Soliman6, Emily M Thudium7, Carla A Sueta5, Anna M Kucharska-Newton3, Sally C Stearns3, Jo E Rodgers2.   

Abstract

RATIONALE, AIMS, AND
OBJECTIVES: Prolongation of the corrected QT (QTc) interval is associated with increased morbidity and mortality. The association between QTc interval-prolonging medications (QTPMs) and risk factors with magnitude of QTc interval lengthening is unknown. We examined the contribution of risk factors alone and in combination with QTPMs to QTc interval lengthening.
METHOD: The Atherosclerosis Risk in Communities study assessed 15 792 participants with a resting, standard 12-lead electrocardiogram and ≥1 measure of QTc interval over 4 examinations at 3-year intervals (1987-1998). From 54 638 person-visits, we excluded participants with QRS ≥ 120 milliseconds (n = 2333 person-visits). We corrected the QT interval using the Bazett and Framingham formulas. We examined QTc lengthening using linear regression for 36 602 person-visit observations for 14 160 cohort members controlling for age ≥ 65 years, female sex, left ventricular hypertrophy, QTc > 500 milliseconds at the prior visit, and CredibleMeds categorized QTPMs (Known, Possible, or Conditional risk). We corrected standard errors for repeat observations per person.
RESULTS: Eighty percent of person-visits had at least one risk factor for QTc lengthening. Use of QTPMs increased over the 4 visits from 8% to 17%. Among persons not using QTPMs, history of prolonged QTc interval and female sex were associated with the greatest QTc lengthening, 39 and 12 milliseconds, respectively. In the absence of risk factors, Known QTPMs and ≥2 QTPMs were associated with modest but greater QTc lengthening than Possible or Conditional QTPMs. In the presence of risk factors, ≥2 QTPM further increased QTc lengthening. In combination with risk factors, the association of all QTPM categories with QTc lengthening was greater than QTPMs alone.
CONCLUSION: Risk factors, particularly female sex and history of prolonged QTc interval, have stronger associations with QTc interval lengthening than any QTPM category alone. All QTPM categories augmented QTc interval lengthening associated with risk factors.
© 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  QTc interval; QTc prolonging medications; risk factors; torsade de pointes

Mesh:

Year:  2017        PMID: 28695724      PMCID: PMC5741511          DOI: 10.1111/jep.12776

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  32 in total

1.  Assessment and control for confounding by indication in observational studies.

Authors:  B M Psaty; T D Koepsell; D Lin; N S Weiss; D S Siscovick; F R Rosendaal; M Pahor; C D Furberg
Journal:  J Am Geriatr Soc       Date:  1999-06       Impact factor: 5.562

2.  Frequency of high-risk use of QT-prolonging medications.

Authors:  Nancy M Allen LaPointe; Lesley H Curtis; K Arnold Chan; Judith M Kramer; Jennifer Elston Lafata; Jerry H Gurwitz; Marsha A Raebel; Richard Platt
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-06       Impact factor: 2.890

Review 3.  AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology.

Authors:  Pentti M Rautaharju; Borys Surawicz; Leonard S Gettes; James J Bailey; Rory Childers; Barbara J Deal; Anton Gorgels; E William Hancock; Mark Josephson; Paul Kligfield; Jan A Kors; Peter Macfarlane; Jay W Mason; David M Mirvis; Peter Okin; Olle Pahlm; Gerard van Herpen; Galen S Wagner; Hein Wellens
Journal:  J Am Coll Cardiol       Date:  2009-03-17       Impact factor: 24.094

4.  QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.

Authors:  J G Reilly; S A Ayis; I N Ferrier; S J Jones; S H Thomas
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

5.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  Circulation       Date:  2010-02-08       Impact factor: 29.690

6.  Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients.

Authors:  Lesley H Curtis; Truls Østbye; Veronica Sendersky; Steve Hutchison; Nancy M Allen LaPointe; Sana M Al-Khatib; Sally Usdin Yasuda; Peter E Dans; Alan Wright; Robert M Califf; Raymond L Woosley; Kevin A Schulman
Journal:  Am J Med       Date:  2003-02-01       Impact factor: 4.965

7.  Evaluation of the dofetilide risk-management program.

Authors:  Nancy M Allen LaPointe; Anita Chen; Bradley Hammill; Elizabeth DeLong; Judith M Kramer; Robert M Califf
Journal:  Am Heart J       Date:  2003-11       Impact factor: 4.749

8.  The QT interval and risk of incident atrial fibrillation.

Authors:  Mala C Mandyam; Elsayed Z Soliman; Alvaro Alonso; Thomas A Dewland; Susan R Heckbert; Eric Vittinghoff; Steven R Cummings; Patrick T Ellinor; Bernard R Chaitman; Karen Stocke; William B Applegate; Dan E Arking; Javed Butler; Laura R Loehr; Jared W Magnani; Rachel A Murphy; Suzanne Satterfield; Anne B Newman; Gregory M Marcus
Journal:  Heart Rhythm       Date:  2013-07-18       Impact factor: 6.343

9.  An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)

Authors:  A Sagie; M G Larson; R J Goldberg; J R Bengtson; D Levy
Journal:  Am J Cardiol       Date:  1992-09-15       Impact factor: 2.778

10.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

View more
  4 in total

1.  Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death.

Authors:  Timothy F Simpson; James W Salazar; Eric Vittinghoff; Joanne Probert; Alan Iwahashi; Jeffrey E Olgin; Phillip Ursell; Amy Hart; Ellen Moffatt; Zian H Tseng
Journal:  JAMA Intern Med       Date:  2020-05-01       Impact factor: 21.873

2.  Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End-Stage Kidney Disease.

Authors:  Magdalene M Assimon; Lily Wang; Patrick H Pun; Wolfgang C Winkelmayer; Jennifer E Flythe
Journal:  J Am Heart Assoc       Date:  2020-06-24       Impact factor: 5.501

3.  Reply to Comment on Lecca, L.I.; Portoghese, I.; Mucci, N.; Galletta, M.; Meloni, F.; Pilia, I.; Marcias, G.; Fabbri, D.; Fostinelli, J.; Lucchini, R.G.; Cocco, P.; Campagna, M. Association between Work-Related Stress and QT Prolongation in Male Workers.

Authors:  Luigi Isaia Lecca; Igor Portoghese; Nicola Mucci; Maura Galletta; Federico Meloni; Ilaria Pilia; Gabriele Marcias; Daniele Fabbri; Jacopo Fostinelli; Roberto G Lucchini; Pierluigi Cocco; Marcello Campagna
Journal:  Int J Environ Res Public Health       Date:  2020-01-14       Impact factor: 3.390

4.  Association between Work-Related Stress and QT Prolongation in Male Workers.

Authors:  Luigi Isaia Lecca; Igor Portoghese; Nicola Mucci; Maura Galletta; Federico Meloni; Ilaria Pilia; Gabriele Marcias; Daniele Fabbri; Jacopo Fostinelli; Roberto G Lucchini; Pierluigi Cocco; Marcello Campagna
Journal:  Int J Environ Res Public Health       Date:  2019-11-28       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.